ANTIBIOTIC use — and misuse — is the main driver for selection of antibiotic-resistant bacteria, and this has led many countries to implement interventions designed to reduce overall antibiotic consumption.
Now, using methicillin-resistant Staphylococcus aureus (MRSA) as an example, Laura Temime of the Conservatoire National des Arts et Metiers in Paris, France, and collaborators are warning that simply reducing antibiotic consumption does not necessarily reduce resistance. The research was published online ahead of print in Antimicrobial Agents & Chemotherapy.
The success of antibiotic reduction programs depends on which antibiotics are reduced, because some select more strongly for resistance than others.
For instance, in the case of S. aureus, reducing the use of clindamycin and methicillin leads to decreased resistance, while reducing use of penicillins does not since most strains of S. aureus, including MRSA, are already resistant to penicillin, Temime explained.
Additionally, efforts to reduce antibiotic use must be coordinated between hospitals and the community since either can feed resistant bacteria into the other, thus undermining reduction efforts, Temime said.
In 2002-03, a national program reduced antibiotic use in France by 10%. However, it fell short of the full potential for reducing resistance because it failed to target those antibiotics that generate the most resistance, Temime said.
She and her collaborators developed a mathematical model of MRSA circulation that correctly simulated that reduction, post-facto. They then performed a number of simulations of reductions in antibiotic use that demonstrated the complexities of reduction efforts.
"We found that the reduction in MRSA hospital rates could have been much larger than it actually was following the 2002 antibiotic reduction campaign," Temime said. "Our results also suggest that changes in the distribution of antibiotics prescribed for non-hospitalized patients actually limited the impact of the antibiotic reduction campaign in French hospitals."
Their research shows that class-specific changes in antibiotic use, rather than overall reductions, need to be considered in order to achieve the greatest benefit from antibiotic reduction campaigns, Temime said.
"This underlines the importance of generating surveillance data on both antibiotic class-specific changes in antibiotic use and antibiotic resistance in the years following an antibiotic reduction campaign. We believe that this research may help health policy-makers and physicians in the design of more efficient antibiotic reduction campaigns."
Formal publication is scheduled for the September 2013 issue of Antimicrobial Agents & Chemotherapy, a publication of the American Society for Microbiology.